Show simple item record

dc.contributor.authorKrieger, Ekaterina Anatoljevna
dc.contributor.authorKudryavtsev, Alexander V
dc.contributor.authorSharashova, Ekaterina
dc.contributor.authorPostoev, Vitaly
dc.contributor.authorBelova, Natalia
dc.contributor.authorShagrov, Leonid
dc.contributor.authorZvedina, Julia
dc.contributor.authorDrapkina, Oxana
dc.contributor.authorKontsevaya, Anna
dc.contributor.authorShalnova, Svetlana
dc.contributor.authorBrenn, Tormod
dc.contributor.authorShkolnikov, Vladimir M.
dc.contributor.authorEggo, Rosalind M.
dc.contributor.authorLeon, David Adrew
dc.date.accessioned2022-09-20T09:17:09Z
dc.date.available2022-09-20T09:17:09Z
dc.date.issued2022-02
dc.description.abstractPopulation-based data on coronavirus disease in Russia and on the immunogenicity of the Sputnik V vaccine are sparse. In a survey of 1,080 residents of Arkhangelsk 40–75 years of age, 65% were seropositive for IgG. Fifteen percent of participants had been vaccinated; of those, 97% were seropositive.en_US
dc.identifier.citationKrieger, Kudryavtsev, Sharashova, Postoev, Belova, Shagrov, Zvedina, Drapkina, Kontsevaya, Shalnova, Brenn, Shkolnikov, Eggo, Leon DA. Seroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russia. Emerging Infectious Diseases. 2022;28(2):463-465en_US
dc.identifier.cristinIDFRIDAID 2024484
dc.identifier.doi10.3201/eid2802.211640
dc.identifier.issn1080-6040
dc.identifier.issn1080-6059
dc.identifier.urihttps://hdl.handle.net/10037/26869
dc.language.isoengen_US
dc.publisherCenters for Disease Control and Preventionen_US
dc.relation.journalEmerging Infectious Diseases
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.titleSeroprevalence of SARS-Cov-2 Antibodies in Adults, Arkhangelsk, Russiaen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record